BioStock: Phase I/II data boosts Coegin Pharma

08 April 2022 - 11:34

The first readout from Coegin Pharma’s COAK phase I/II study in actinic keratosis has produced positive results. The top-line data indicates excellent safety and tolerance of AVX001 in 60 patients evaluated with two different doses. BioStock reached out to Coegin’s CEO Tore Duvold to get his perspective on the data.

Read the interview with Coegin's CEO Tore Duvold at

This is a press release from BioStock - Connecting Innovation & Capital

Provided by: Cision
NGM Nordic SME (Sweden)
Coegin Pharma AB
Coegin Pharma specializes in molecular therapy which is further used in therapeutic treatments. Examples of diseases for which the company's solutions are used include cancer, leukemia and chronic kidney disease....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More